Dupont Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Dupont Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,856	Closed	-$92K	–	1463
2022 Q3	$92K	Sell	8,856 -28,551	-76%	-$318K	0.01%	1068
2022 Q2	$402K	Hold	37,407	–	–	0.02%	792
2022 Q1	$354K	Sell	37,407 -3,309	-8%	-$31K	0.01%	880
2021 Q4	$470K	Sell	40,716 -16,234	-29%	-$181K	0.02%	833
2021 Q3	$544K	Sell	56,950 -8,050	-12%	-$82.3K	0.02%	818
2021 Q2	$627K	Hold	65,000	–	–	0.01%	863
2021 Q1	$642K	Buy	65,000 +36,972	+132%	+$572K	0.02%	811
2020 Q4	$647K	Sell	28,028 -2,092	-7%	-$42.8K	0.01%	733
2020 Q3	$425K	Sell	30,120 -2,018	-6%	-$29.4K	0.01%	825
2020 Q2	$485K	Sell	32,138 -2,870	-8%	-$35K	0.01%	797
2020 Q1	$323K	Hold	35,008	–	–	0.01%	827
2019 Q4	$341K	Hold	35,008	–	–	0.01%	1021
2019 Q3	$281K	Buy	+35,008	New	+$380K	0.01%	1026

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Dupont Capital Management's FOLD Position: Q4 2022 in Review

Dupont Capital Management sold out of Amicus Therapeutics (FOLD) in Q4 2022, closing a stake of 8,856 shares — an estimated $92K sold.

Dupont Capital Management first reported a position in FOLD in Q3 2019 and held it in 13 quarters. The position peaked at $647K in Q4 2020. 230 funds tracked by Wall St. Rank hold FOLD as of Q4 2022.

Dupont Capital Management reported no remaining Amicus Therapeutics position as of Q4 2022 after selling out during the quarter.
Dupont Capital Management sold 8,856 Amicus Therapeutics shares in Q4 2022, an estimated $92K.
Dupont Capital Management first reported a position in Amicus Therapeutics in Q3 2019 and held it in 13 quarters.
Dupont Capital Management's Amicus Therapeutics position peaked at $647K in Q4 2020.
230 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2022.

Based on Dupont Capital Management's 13F filing for Q4 2022, filed 26 Jan 2023.